

November 13, 2007

AnGes MG, Inc.

**AnGes MG, Inc., Signs Licensing Deal with Meyer Pharmaceuticals, LLC
- The Development and Marketing of
NF- κ B Decoy Oligo in North America and Europe-**

AnGes MG, Inc. (AnGes) announced today that it has entered into an agreement granting the exclusive right of development and marketing of NF- κ B Decoy Oligo in North America and in Europe with Meyer Pharmaceuticals, LLC (Meyer Pharmaceuticals). By this partnership, AnGes is looking forward to the opportunity to develop NF- κ B Decoy Oligo as a therapeutic agent in North America and Europe.

In this agreement, Meyer Pharmaceuticals has exclusive development and marketing rights of NF- κ B Decoy Oligo for local treatment of skin disease (excluding psoriasis in Europe), respiratory disease, orthopedic disease and inflammatory bowel disease in North America and Europe. (In Europe, AnGes has the right to retain from the co-promotion.) Meyer Pharmaceuticals will sponsor all clinical development for these local treatment targets.

Meyer Pharmaceuticals was established in 1996 as a bio-venture to specialize in cancer immune treatment and inflammation diseases in order to move the research results of the University of California into clinical development. Meyer Pharmaceuticals' business strategy encompasses strengthening its research and development in immune related fields by in-licensing NF- κ B Decoy Oligo.

Meyer Pharmaceuticals was established by Mr. Robert Meyer as the sole investor. Besides his corporate holding group dealing with the pharmaceutical business, Mr. Meyer holds stakes in various types of business entities including Meyer Natural Angus® livestock business, real estate holdings, and other fields.

Under the terms of this contract AnGes will receive an upfront fee and milestone payments depending on progress of the development in every region and disease area. Furthermore, when the NF- κ B Decoy Oligo achieves successful development and approval, and the product is marketed, AnGes will share the profit with Meyer Pharmaceuticals. Upon development of all eight possible indications, AnGes will receive a total amount of USD 223 million in milestone payments.

AnGes will receive an upfront payment from Meyer Pharmaceuticals. However, this financial impact has already been included in its present fiscal year's earnings forecast.

<Reference>

Meyer Pharmaceuticals LLC

Headquarters: 1761 Kaiser Avenue, Irvine, CA 92614 U.S.A.

President and CEO: Michael F. O'Neill

Number of employees: Approx. 18

Business: Research and development of drugs